Intrust Bank NA Acquires 309 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Intrust Bank NA grew its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 10.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,350 shares of the pharmaceutical company’s stock after buying an additional 309 shares during the quarter. Intrust Bank NA’s holdings in Vertex Pharmaceuticals were worth $1,363,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the business. Sherbrooke Park Advisers LLC grew its position in shares of Vertex Pharmaceuticals by 65.3% in the third quarter. Sherbrooke Park Advisers LLC now owns 2,645 shares of the pharmaceutical company’s stock valued at $920,000 after purchasing an additional 1,045 shares in the last quarter. Robeco Institutional Asset Management B.V. boosted its position in Vertex Pharmaceuticals by 6.5% during the third quarter. Robeco Institutional Asset Management B.V. now owns 432,937 shares of the pharmaceutical company’s stock valued at $150,550,000 after buying an additional 26,523 shares during the period. Telos Capital Management Inc. grew its position in Vertex Pharmaceuticals by 1.6% during the 4th quarter. Telos Capital Management Inc. now owns 15,073 shares of the pharmaceutical company’s stock worth $6,133,000 after acquiring an additional 237 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Vertex Pharmaceuticals by 1.3% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 427,001 shares of the pharmaceutical company’s stock worth $148,485,000 after purchasing an additional 5,514 shares during the last quarter. Finally, Machina Capital S.A.S. bought a new stake in Vertex Pharmaceuticals in the 3rd quarter worth $816,000. 90.96% of the stock is currently owned by institutional investors.

Insider Activity

In other Vertex Pharmaceuticals news, COO Stuart A. Arbuckle sold 4,295 shares of the business’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $1,804,930.80. Following the completion of the transaction, the chief operating officer now directly owns 75,718 shares in the company, valued at $31,819,732.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, COO Stuart A. Arbuckle sold 4,295 shares of the company’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,804,930.80. Following the transaction, the chief operating officer now directly owns 75,718 shares of the company’s stock, valued at approximately $31,819,732.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Ourania Tatsis sold 480 shares of the firm’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $420.79, for a total value of $201,979.20. Following the completion of the sale, the executive vice president now directly owns 59,827 shares of the company’s stock, valued at approximately $25,174,603.33. The disclosure for this sale can be found here. In the last three months, insiders have sold 12,381 shares of company stock worth $5,203,249. 0.20% of the stock is currently owned by company insiders.

Vertex Pharmaceuticals Trading Down 0.4 %

Shares of NASDAQ VRTX traded down $1.68 during trading hours on Tuesday, reaching $394.52. The stock had a trading volume of 65,273 shares, compared to its average volume of 1,206,091. The business’s fifty day moving average price is $411.08 and its two-hundred day moving average price is $399.37. The firm has a market cap of $101.97 billion, a price-to-earnings ratio of 28.52, a P/E/G ratio of 1.87 and a beta of 0.35. Vertex Pharmaceuticals Incorporated has a 52-week low of $320.01 and a 52-week high of $448.40. The company has a current ratio of 3.99, a quick ratio of 3.78 and a debt-to-equity ratio of 0.02.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.85 by $0.35. The company had revenue of $2.52 billion for the quarter, compared to analysts’ expectations of $2.50 billion. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. During the same period in the prior year, the business earned $3.33 EPS. Analysts expect that Vertex Pharmaceuticals Incorporated will post 14.95 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

VRTX has been the topic of several research analyst reports. Wells Fargo & Company boosted their price target on shares of Vertex Pharmaceuticals from $500.00 to $540.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. UBS Group cut their target price on shares of Vertex Pharmaceuticals from $498.00 to $466.00 and set a “buy” rating for the company in a research report on Wednesday, April 17th. Cantor Fitzgerald restated an “overweight” rating and set a $440.00 price target on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 20th. Guggenheim raised their target price on Vertex Pharmaceuticals from $445.00 to $450.00 and gave the stock a “buy” rating in a report on Thursday, April 18th. Finally, Robert W. Baird lowered shares of Vertex Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $325.00 price target for the company. in a research report on Wednesday, January 31st. Three analysts have rated the stock with a sell rating, six have issued a hold rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $429.45.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.